JaanBio announces that a National Institute of Health grant of $225,000 has been awarded to Jaan Bio under the NIH Small Business Innovative Research program.
Online PR News – 18-March-2017 – San Diego, CA – March 16, 2017 – Jaan Biotherapeutics L.L.C. (Jaan Bio) (https://www.JanBio.com) is a drug development company focused on heart muscle regeneration for Ischemic Heart Disease, Duchenne Muscular Dystrophy, and Hypertrophic Cardiomyopathy.
We are excited to announce that a National Institute of Health (NIH) grant of $225,000, Grant Number: 1R41HL134387, has been awarded to Jaan Bio under the NIH Small Business Innovative Research program (STTR).
The purpose of the grant is for further research to determine the efficacy of an innovative ribonucleic acid interference technology to regenerate ischemic damaged cardiac muscle by reactivating an evolutionary conserved process. Jaan Bio is translating this research developed by the laboratory of Professor Juan Carlos Izpisua Belmonte of the Salk Institute for Biological Studies, La Jolla, CA into therapeutics.
Ischemic Heart Disease is the single largest cause of death worldwide and approximately 735,000 people in the U.S. suffer heart attacks every year as stated by the American Heart Association- Heart Disease and Stroke Statistics—2015.
About Jaan Biotherapeutics L.L.C.
Founded in San Diego in 2015, Jaan Bio is a private biopharmaceutical company engaged in finding therapies to regenerate heart muscle by modulating the activity of microRNAs.
Jaan Biotherapeutics L.L.C.
6331 Nancy Ridge Drive, Suite 204
San Diego, CA 92121